The design utilizes bilateral stimulation and offers a leadless, full-body 1.5T and 3T MRI-compatible, non-implanted battery solution that is powered and controlled by a wearable component.| Sleep Review
Inspire CEO Timothy P. Herbert detailed the challenges Inspire V is facing in the US marketplace.| Sleep Review
Data from Nyxoah SA’s DREAM pivotal study has been published online in a peer-reviewed journal, revealing 12-month safety and efficacy results for the company’s CE-marked Genio bilateral hypoglossal nerve stimulator.| Sleep Review
The next-generation Inspire V streamlines the implant procedure by eliminating the need for a separate sensing lead.| Sleep Review
The USPTO has awarded Nexalin Technology Inc a new patent relating to its method of use, which covers key aspects of the technology that enables patients to receive treatment from the privacy of their homes.| Sleep Review